1. P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA. (5th April 2022) Authors: Usmani, S; Alonso, A; Quach, H; Koh, Y; Guenther, A; Min, CK; Leleu, X; Abdallah, AO; Oriol, A; Bessemer, B; Garg, M; Sandhu, I; Weisel, K; Ocio San Miguel, E; Cavo, M; Zhou, X; Kaisermann, M; Mis, L; Williams, D; Yeakey, A Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P15: EVOLUTION OF MULTIPLE MYELOMA TREATMENT PATTERNS FROM 2015 THROUGH 2019: REAL-WORLD EVIDENCE FROM A EUROPEAN DATABASE STUDY. (5th April 2022) Authors: Oriol Rocafiguera, A; Steinmetz, T H; Brescianini, A; Gonzalez-McQuire, S; Eugene, N; Abbasi, A; Wetten, S; Leleu, X Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P24: EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE LENALIDOMIDE-SPARING REGIMENS IN EUROPE. (5th April 2022) Authors: Mateos, M; Leleu, X; Zamagni, E; Delforge, M; Bringhen, S; Broijl, A; de la Rubia, J; Shaw, A; Brescianini, A; Gonzalez-McQuire, S; Patel, S; Moreau, P Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. THU0255 A new bone prognostic factor in multiple myeloma (mm): level serum cross-laps (ctx) at diagnosis. (1st June 2001) Authors: Duché, A; Leleu, X; Duhamel, A; Delannoy, V; Facon, T; Brazier, M Journal: Annals of the rheumatic diseases Issue: Volume 60(2001)Supplement 1 Page Start: A313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗